Chicago Capital’s Immunic IMUX Stock Holding History

Chicago Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-63	Closed	-$7K	–	211
2018 Q3	$7K	Sell	63 -186	-75%	-$486K	﹤0.01%	221
2018 Q2	$682K	Hold	249	–	–	0.06%	129
2018 Q1	$677K	Buy	+249	New	+$571K	0.09%	94

Other funds holding IMUX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Chicago Capital's IMUX Position: Q4 2018 in Review

Chicago Capital sold out of Immunic (IMUX) in Q4 2018, closing a stake of 63 shares — an estimated $7K sold.

Chicago Capital first reported a position in IMUX in Q1 2018 and held it in 3 quarters. The position peaked at $682K in Q2 2018. 47 funds tracked by Wall St. Rank hold IMUX as of Q4 2018.

Chicago Capital reported no remaining Immunic position as of Q4 2018 after selling out during the quarter.
Chicago Capital sold 63 Immunic shares in Q4 2018, an estimated $7K.
Chicago Capital first reported a position in Immunic in Q1 2018 and held it in 3 quarters.
Chicago Capital's Immunic position peaked at $682K in Q2 2018.
47 funds tracked by Wall St. Rank held Immunic as of Q4 2018.

Based on Chicago Capital's 13F filing for Q4 2018, filed 11 Feb 2019.